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Abstract 
Multiple Sclerosis (MS) is a chronic auto-immune disease of the Central Nervous System causing 
inflammation and neurodegeneration.  There are only 3 epidemiological studies in Portugal, 2 in the 
Centre and 1 in the North and there is the need to further study MS epidemiology in this country. 
The objective of this work is to contribute to the MS epidemiological knowledge in Portugal, describing 
the patients’ epidemiological, demographic and clinical characteristics in the Braga district of Portugal. 
This is a cross-sectional study of 345 patients followed in two hospitals of Braga district. These 
hospitals cover a resident population of 866,012 inhabitants. The data was collected from the clinical 
records, and it was established 2009/12/31 as the prevalence day. For all MS patients, demographic 
characteristics and clinical outcomes are reported.  
We have found an incidence of 2.74/100,000 and a prevalence of 39.82/100,000 inhabitants. Most 
patients have an EDSS of 3 or lower and a mean age of 42 years old. The diagnosis was done at 
mean age of 35, being RRMS the disease type in more than 80% of patients. In this cohort we found 
a Female:Male ratio of 1.79. More than 50% of patients are treated with Interferon β-1b IM or IFNβ-1a 
SC 22µg. 
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1. Introduction 
Multiple Sclerosis (MS) is a chronic auto-immune disease of the Central Nervous System (CNS) 
causing inflammation and neurodegeneration.  The characteristic demyelination of the neurons, 
followed in many cases by axonal loss and gliosis results in incapacity progression 1. The incapacity 
status is usually assessed in MS patients with the Expanded Disability Status Scale (EDSS) 2. 
Different types of MS have been described based on the clinical course: Relapsing-Remitting Multiple 
Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Primary Progressive Multiple 
Sclerosis (PPMS), Relapsing-Progressing Multiple Sclerosis (RPMS) 3, Clinically Isolated Syndrome 
(CIS) 4 and Benign MS 5.  
There is yet no cure for MS, but several Disease Modifying Treatments have shown to have beneficial 
effects on the disease progression. The approved treatments for MS in Europe include Interferon β-1a 
SC and IM, Interferon β-1b SC, Glatiramer Acetate SC, Natalizumab IV, oral Fingolimod, oral 
Dimethyl Fumarate, oral Teriflunamide and Alemtuzumab IV.  
MS has a great social and economic impact, because it affects mainly young adults 6, who will be 
more prone to unemployment7 and in a big percentage will need a walking aid few years after of 
disease onset 8,9. MS is more prevalent in females 10 and Caucasians11 and it’s influenced by the 
geographic localization (Multiple Sclerosis International Federation).  
Our aim is to contribute to the MS epidemiological knowledge in Portugal, describing the patients’ 
epidemiological, demographic and clinical characteristics. 
 
2. Methods 
The district of Braga is located in the Northwestern part of Portugal. In the district of Braga, there are 
two hospitals with consultation and treatment of Multiple Sclerosis for a resident population of 866,012 
inhabitants (INE).The hospitals are Hospital de São Marcos in the city of Braga (HSM) and Hospital 
Senhora da Oliveira in the city of Guimarães (HSO). Braga is the youngest district of Portugal: 30.7% 
of the population is under 25 years, 56.4% are between 25 and 64 years and 12.9% have more than 
64 years. The population of this district is mostly lower middle class (which covers 37.1% of the 
population).  
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This is a cross-sectional study of MS patients followed in the Braga and Guimarães Hospitals. The 
data was collected from the clinical records, and it was established 2009/12/31 as the prevalence day. 
At the prevalence date only Interferon β-1a SC and IM, Interferon β-1b SC, Glatiramer Acetate SC 
and Natalizumab IV were approved for MS in Europe. All the cases were assessed by a neurologist 
and included in the study whenever they met the Poser diagnostic criteria. Only residents of Braga 
district which had an office visit between 1st January 1997 and 31st December 2009 were included in 
this study. We requested the necessary consent to patients, Portuguese Data Privacy Committee 
(Comissão Nacional de Proteção de Dados) and to the Ethical Committees of both hospitals. There 
were no clinical records for HSM patients before 1997. In order to compare the hospitals, the year of 
diagnosis for HSO patients was considered to be 1997, for every patient that had records older than 
that. 
In this study, for all MS patients, demographic characteristics (sex, age, age at diagnosis, treatment, 
spatial distribution of place of residence) and clinical outcome (type of the disease, treatment, clinical 
severity score [EDSS], year and month of diagnosis) are reported. Student's t-test and Chi-squared 
test were used to evaluate differences between groups. All significance tests were based on p< 0.05 
as the level of significance. 
 
3. Results 
The database is composed of 345 individuals that are followed in the MS outpatient clinic of HSM and 
HSO. The estimated disease prevalence is 39.84 per 100,000 inhabitants (95% CI = 27.47 – 52.21). 
The Female:Male ratio is 1.79, with 64.06% of females MS patients and 35.94% males.  
The mean age at diagnosis is approximately 35 years and varies between 13.61 and 70.55 years. 
(Table 1). At prevalence day the mean age is 42. 
HSM and HSO have a similar distribution of patients over the RRMS and SPMS forms. The number of 
patients with PPMS, CIS and Benign MS forms is too low to compare between hospitals. (Table 2) 
The most common treatment is Interferon β-1b IM, with 29.86%, followed by IFNβ-1a SC 22µg with 
24.64%, Glatiramer Acetate with 17.97%, IFNβ-1a SC 44µg with 12.17%, IFNβ-1a IM with 7.25%, 
Natalizumab IV with 5.51%, and Mitoxantrone 0.29%. 2.32% of patients are without treatment. (Figure 
1) 
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Patients were divided in three groups according to their disability as quantified by the EDSS. Most 
patients have an EDSS of 3 or less. (Figure 2) 
In HSM there were no MS patient records before 1997. HSO MS patients have records for previous 
years but we decided to consider 1997 has the year of diagnosis in those cases. If we assume 
866,012 as the Braga district population from 1998 to 2009, we can estimate an average annual 
incidence of 2.74/100,000 inhabitants in the Braga district. (Figure 3) 
 
 
4. Discussion 
MS patients in Portugal are almost exclusively followed in public hospitals because Disease Modifying 
Treatments (DMTs) are almost only offered to patients without any co-payment in the National Health 
System (NHS) hospitals. As a result, only a very small number of patients, at national level, have 
access to DMTs outside the NHS hospitals. HSM and HSO are the only MS reference centers in the 
district of Braga, so it’s expected that the vast majority of MS patients of this district to be registered in 
one of these two hospitals. There is the possibility that some MS patients from this district are 
followed in other MS centers in Portugal, so the estimated prevalence may be underestimated. To 
more accurately determine the MS prevalence in this district further work should be done.  A cross-
check between the hospitals and the primary care centers patient’s lists would give the most accurate 
prevalence numbers. Additionally, MS patient’s lists from hospitals like Centro Hospitalar de São 
João, Centro Hospitalar do Porto and Centro Hospitalar e Universitário de Coimbra, should be 
checked to capture patients with residence in Braga district but who are followed in those Hospitals. 
For several years Portugal has been considered to be a low-medium prevalence zone for MS 14, but 
recent epidemiological studies suggest that our country should instead be considered a medium 
prevalence zone 15,16. A prevalence study in the district of Santarém 16 determined a prevalence of 
46.3 cases/100,000 in 2006 and a nationwide survey presented in 2011 by J Pinheiro found this 
number to be 54/100,000.17 More recently, a prevalence study in a referral hospital and three 
community health clinics in a large city (Lisboa) determined a prevalence of 56.2/100,000.18 The 
39.84/100,000 prevalence that we estimated in this study is probably underestimated due to the 
exclusion of patients who are resident in Braga district but are followed in other hospitals from cities 
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like Oporto or Coimbra. The 2.74/100,000 annual incidence is lower than the reported for Spain and 
Italy 19, but this value is probably underestimated, for the same reason and also because we 
considered a constant population (equal to 2009 numbers) between 1998 and 2009.  
The gender ratio F:M in this study  is 1.79. In both hospitals the highest number of diagnosis was in 
the year 2008 (excluding 1997) with 11.88% of the patients. The MS diagnostic of HSO patients was 
made at a younger age. The age at diagnosis, patient distribution amongst MS forms and disability 
status assessed by EDSS is also consistent with results from previous MS studies 8,19. Noteworthy is 
the low percentage of patients without treatment, 2.32%.  
5. Conclusion 
The district of Braga is a medium prevalence zone for MS with a prevalence of 39.82/100,000 
inhabitants. We estimated an average annual incidence of 2.74/100,000 inhabitants between 1998 
and 2009. In this study, MS patients’ demographic and clinical characteristics are consistent with what 
was expected in light of current scientific literature.  
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Figure 1 
Most patients are treated with first-line drugs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
10 
 
Figure 2 
The patient distribution in these three EDSS groups is similar in both hospitals (p= 0.0549)  
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Figure 3 
The annual incidence between 1998 and 2009 was 2.74/100,000 
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Table 1. Age at diagnosis 
 
Minimum Maximum Mean Median Std. Deviation 1st Q 3rd Q 
Total 13,61 70,55 35,38 34,91 11,58 26,09 42,24 
HSM 14,82 70,55 36,09 35,84 11,75 26,98 44,41 
HSO 13,61 65,83 33,84 33,22 11,10 25,72 39,85 
 The mean age at diagnosis is 35  
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Table 2. Most of patients have the Relapsing-Remitting form of Multiple Sclerosis 
 
